A Phase 2b, Randomized, Double-blind, Placebo-controlled,
Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability
of Three Doses of Aldafermin Administered for 24 Weeks for the
Treatment of Histologically Confirmed Nonalcoholic Steatohepatitis
(NASH)
Please contact us for more information or to learn if you are eligible to participate.
